Microcephaly Gene Links Trithorax and REST/NRSF to Control Neural Stem Cell Proliferation and Differentiation

Yawei J. Yang,1,3,4,5,7,8 Andrew E. Baltus,1,7,16 Rebecca S. Mathew,6,7 Elisabeth A. Murphy,1,7,9 Gilad D. Evrony,1,3,4,5,7 Dilenny M. Gonzalez,1,7 Estee P. Wang,1,3,7,16,17 Christine A. Marshall-Walker,1,7,16 Brenda J. Barry,1,7 Jernej Murn,2,6 Antonis Tatarakis,6,7 Muktar A. Mahajan,11 Herbert H. Samuels,11 Yang Shi,2,6 Jeffrey A. Golden,12 Muhammad Mahajnah,13,15 Ruthie Shenhav,14,15 and Christopher A. Walsh1,3,4,7,*

1Division of Genetics and Manton Center for Orphan Disease Research
2Division of Newborn Medicine
Boston Children’s Hospital, Boston, MA 02115, USA
3Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
4Program in Biological and Biomedical Sciences
5Harvard MD-PhD MSTP Program
6Department of Cell Biology
Harvard Medical School, Boston, MA 02115, USA
7Howard Hughes Medical Institute, 4000 Jones Bridge Road, Chevy Chase, MD 20815, USA
8Harvard-MIT Division of Health Sciences and Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
9Department of Neuroscience, Northeastern University, Boston, MA 02115, USA
10Harvard School of Dental Medicine, Boston, MA 02115, USA
11Department of Pharmacology and Medicine, New York University School of Medicine, New York, NY 10016, USA
12Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115, USA
13Child Development and Pediatric Neurology, Hillel Yaffe Medical Center, Hadera 38100, Israel, The Technion, Israel Institute of Technology, Haifa 32000, Israel
14Raphael Recanati Genetics Institute, Rabin Medical Center, Beilinson Campus, Petah Tikva 49100, Israel
15These authors contributed equally to this work
16Present address: Addgene, Cambridge, MA 02139, USA
17Present address: Department of Orthodontics, University of Michigan, Ann Arbor, MI 48109, USA
18Present address: Phillips Academy Andover, Andover, MA 01810, USA
*Correspondence: christopher.walsh@childrens.harvard.edu
http://dx.doi.org/10.1016/j.cell.2012.10.043

SUMMARY

Microcephaly is a neurodevelopmental disorder causing significantly reduced cerebral cortex size. Many known microcephaly gene products localize to centrosomes, regulating cell fate and proliferation. Here, we identify and characterize a nuclear zinc finger protein, ZNF335/NIF-1, as a causative gene for severe microcephaly, small somatic size, and neonatal death. Znf335 null mice are embryonically lethal, and conditional knockout leads to severely reduced cortical size. RNA-interference and post-mortem human studies show that ZNF335 is essential for neural progenitor self-renewal, neurogenesis, and neuronal differentiation. ZNF335 is a component of a vertebrate-specific, trithorax H3K4-methylation complex, directly regulating REST/NRSF, a master regulator of neural gene expression and cell fate, as well as other essential neural-specific genes. Our results reveal ZNF335 as an essential link between H3K4 complexes and REST/NRSF and provide the first direct genetic evidence that this pathway regulates human neurogenesis and neuronal differentiation.

INTRODUCTION

Brain development requires carefully regulated yet continuously changing patterns of gene and protein expression. Cerebral cortical neurons are formed from progenitors that at the earliest stages divide mainly symmetrically to expand the progenitor population. At later stages, these apical progenitors divide increasingly in an asymmetrical fashion to produce one progenitor cell and a second more differentiated cell—either a neuron or a transit-amplifying progenitor cell that resides in the subventricular zone (Lui et al., 2011). Eventually, symmetrical divisions of progenitors are increasingly replaced by neurogenic cell divisions that produce the neurons of the cerebral cortex in an inside-first, outside-last sequence (Fietz and Huttner, 2011). Although much is known about the cellular patterns of neurogenesis, the molecular controls of this process remain relatively poorly understood.
Figure 1. A New Syndrome of Severe Microcephaly and Neuronal Degeneration

(A) Pedigree of family with severe microcephaly. (Double lines) Consanguineous marriages; (black shading) known affected; (diagonal line) deceased at time of publication; (asterisk) sequence analysis was completed on the individual.

(B) Cortical histology of patient versus age-matched controls at 10x (left) and 40x (right) magnification. Patients show decreased cortical thickness and abnormal cortical layers. Scale bar, 300 μm.

(C) MRI of patient versus age-matched control shows decreased brain size, including cerebellum and brain stem, increased extraaxial space, and enlarged ventricles. Whole brains are outlined in yellow, showing separation of brain from skull.

(D) Patient Cerebellum

---

(E) Patient

---

Control

---

Cell 151, 1097–1112, November 21, 2012 ©2012 Elsevier Inc.
Naturally occurring mutations of human cerebral cortical development have provided surprising genetic insights into the process of neurogenesis in vertebrates. Genetic causes of microcephaly implicate components of the mitotic spindle and proteins involved in DNA repair (Mahmood et al., 2011; Mochida, 2009; Thornton and Woods, 2009). However, human microcephaly genes have so far generally not highlighted the transcriptional pathways that animal studies implicate as essential to cerebral cortical neurogenesis (Molyneaux et al., 2007).

A key aspect of the regulation of gene expression during neurogenesis occurs at the level of chromatin structure. Acetylation, methylation, and phosphorylation of histone proteins affect the access of transcriptional proteins to DNA wrapped around nucleosomes (Bannister and Kouzarides, 2011), contributing to the complex control of gene expression. The trithorax (TrxG) and polycomb (PcG) chromatin-remodeling complexes work in opposition to activate or silence gene expression, respectively (Ng and Gurdon, 2008). Recent studies shed light on the importance of chromatin regulatory complexes in brain development and developmental disease, although focus is placed mostly on PcG complex proteins and adult neurogenesis (Lessard and Crabtree, 2010; Ma et al., 2010). TrxG regulates developmental expression of many genes that are important for patterning, cell proliferation, and stem cell identity by maintaining genes in an active state (Fisher and Fisher, 2011). The TrxG complex activates gene expression through the methylation of lysine 4 on histone H3 (H3K4) (Papp and Müller, 2006), a marker of actively transcribed genes or genes poised for transcription (Bernstein et al., 2005). SET1 methyltransferases (MLL1, MLL2, and SET1A/B) are the major enzymes carrying out H3K4 methylation, functioning in a multiprotein complex with Ash2L, WDR5, and RbBP5 (Schuettengruber et al., 2011). Although TrxG has been implicated in Drosophila development (Paro et al., 1998) and members of the complex have been implicated in vertebrate development and embryonic stem cells (Ang et al., 2011), the role of TrxG has not been well studied in neural stem cells or in human brain development (Schuettengruber et al., 2011).

Another critical epigenetic regulator of neurogenesis is the repressor element 1 (RE1)-silencing transcription factor (REST)/neuron-restrictive silencer factor (NRSF) (Chong et al., 1995; Schoenherr and Anderson, 1995). REST/NRSF acts as a transcriptional repressor through the recruitment of histone deacetylases (HDACs), which place chromatin in a condensed state via the removal of acetyl residues (Ballas et al., 2005). REST/NRSF is expressed in neural stem cells and is essential for maintaining progenitor cell fate by inhibiting neuronal specific genes (Sun et al., 2005). REST/NRSF has also been suggested to play roles in embryonic stem cells as well as mature cell types (Ballas et al., 2005; Johnson et al., 2008); however, the upstream regulation of REST/NRSF, as well as the interaction of REST/NRSF and TrxG, two central epigenetic regulators of neurogenesis, is unknown.

In this study, we identify a new regulator of vertebrate neurogenesis, ZNF335, in a family that presents with one of the most severe cases of microcephaly documented. ZNF335 was previously cloned and identified as a coregulator (NRC-interacting factor 1 [Nif1]) of nuclear hormone signaling (Garapaty et al., 2009) and as part of a complex containing components known to be involved in histone H3 methylation, but its functions have never been studied in vivo. We show that ZNF335 is essential for normal brain development in human and mouse and that ZNF335 interacts with a H3K4 chromatin methyltransferase complex. ChIP-PCR, ChIP-seq, RNA-seq, and microarray studies reveal that ZNF335 is essential for methylation and expression of brain-specific genes including the master progenitor regulator REST/NRSF. Knockdown of ZNF335 disrupts progenitor cell proliferation, cell fate, and neuronal differentiation. Brain-specific knockout leads to severely reduced to absent forebrain structure. Together, these data define an essential control system for REST/NRSF expression and implicate a new microcephaly gene that coordinates global transcriptional regulation in brain development to affect cell fate.

RESULTS

A New Syndrome of Profound Microcephaly, Neuronal Degeneration, and Neonatal Death

A large consanguineous Arab Israeli pedigree presented with seven individuals (two of them identical twins) affected with one of the most severe cases of microcephaly (MCPH) seen to date (head circumference 9 standard deviations below mean) and death by 1 year of age in all but one case (Figures 1A–1C). MRI at 3 months of age revealed extreme microcephaly with a severely simplified gyral pattern (Figure 1C). The cerebral cortex was even more notably smaller than the skull, with subarachnoid fluid separating the two, an indication of secondary shrinkage of the brain usually reflecting degeneration (Barkovich et al., 2007). Histopathology of Patient 5 at 7 months of age revealed a thinned cerebral cortex and neuronal disorganization, with only about 20% of the cortex showing the normal six cortical layers (Figure 1B). The few neurons that were present demonstrated little apparent polarity or dendritic maturation. Layer I, a normally cell-sparse layer containing many neuronal processes, was severely reduced in thickness, potentially reflecting defects in process outgrowth and/or defects of layer I Cajal-Retzius cells. Layers II–VI, normally neuron rich, showed sparse neurons of abnormally small size, suggesting incomplete neuronal differentiation. Well-differentiated pyramidal neurons, normally the most abundant neuron in the cortex, were also almost completely unidentifiable because of either aberrant differentiation or severely reduced numbers (Figure 1B).

(D) Cerebellar histology. Calbindin-stained sections of patients versus age-matched controls. Patients have persistent external granule cell layer (EGL), decreased molecular layer (ML), abnormal Purkinje cell layer (PCL), and decreased internal granule cell layer (IGL). Scale bar, 100 μm.

(E) Patients have unmigrated EGL cells (top, arrow) above a thinner molecular layer. Patients have severely reduced granule cell density compared to control (bottom, arrowhead). Scale bar, 50 μm.

See also Extended Experimental Procedures.
Figure 2. Severe Microcephaly Reflects a Splicing/Missense Mutation ZNF335

(A) Patients show linkage at chromosome 20q13.12. Sequencing shows a c.3332g>a mutation in gene ZNF335. (Top) Schematic of chromosome 20. (Middle) Single-nucleotide polymorphism genotyping. Each column represents a SNP, and the red and blue indicate homozygosity, whereas yellow shows heterozygosity. A large region (boxed) shows mainly red and blue SNPs in affected patients with heterozygosity in parents. (Bottom) Representative sequencing data.

(B) Mutation is at a 5' splice site of ZNF335 and leads to p.R1111>H missense mutation.

(C) Northern blot shows production of a new larger transcript (*) in heterozygous parents and homozygous patients. Amino acid sequence (green); exon sequence (blue); intron sequence (yellow); mutation (red).

(D) Schematic of exons and intronic splicing for a control, and the predicted problems with intronic splicing in a patient with a c.3332g>a mutation. Schematic of RNA-seq data shows detection of reads within exons (blue) and within introns (yellow) upstream and downstream of the mutation-containing exon. Incomplete splicing is present in heterozygous parents (Het) and homozygous patients (Hom), but not in control cells. RNA-seq data also detected the base change mutation (*).

(E) Schematic of exons and introns, showing the site of mutation in ZNF335.

(F) Western blot for full-length ZNF335 shows differences in expression levels between control, parent, and affected individuals. Beta-Actin was used as a loading control.

1100 Cell 151, 1097–1112, November 21, 2012 ©2012 Elsevier Inc.
The cerebellum showed severely reduced external as well as internal granule cell layers (EGL, IGL), which normally contain granule cell precursors and granule cells at this age (Figure 1D), suggesting widespread loss. There were few Purkinje cells and increased numbers of eosinophilic gemistocytic astrocytes in the Purkinje cell layer (PCL), consistent with a degenerative process. Calbindin immunoreactivity highlighted the severely reduced number and abnormal localization and orientation of the rare remaining Purkinje cells (Figure 1D). A few mature granule cells persisted in the EGL (Figure 1E, top), suggesting defective migration into the IGL. There is also a strikingly cell-sparse IGL, normally the location of countless mature granule cells (Figure 1E, bottom), suggesting profound defects in generation and/or survival. These postmortem histological studies suggest that the responsible gene has essential roles in normal neurogenesis, neuronal migration, and neuronal polarity, as well as neuronal survival. The small birth weight and length and other somatic features indicate that somatic size was affected, as well as brain size (Extended Experimental Procedures available online).

**A Splice Donor/Missense Mutation of ZNF335 Causes Severe Microcephaly**

The genetic mutation was identified by linkage mapping and gene sequencing and was confirmed and further characterized using mRNA-transcriptome sequencing (RNA-seq). Mapping using single-nucleotide polymorphism (SNP) arrays, followed by fine mapping, identified a single ~2 Mb interval that was homozygous and identical by descent in all affected pedigree members (Figure 2A) and in none of the unaffected individuals (multipoint logarithm of odds [LOD] = 4.54). Sequence analysis of the 40 genes in the minimal linked region showed only one homozygous nonsynonymous change not already identified in dbSNP: a G-to-A transition at position 3332 of the coding sequence of the ZNF335 gene. All affected individuals were homozygous for this mutation, all parents were heterozygous, and an unaffected sibling was wild-type, consistent with an autosomal recessive mode of inheritance (Figures 1A and 2A). This change was absent from 100 Middle Eastern control patients, 200 sequenced-unaffected Arabic control exomes, and 2,500 European control exomes (NHBLI GO Exome Sequencing Project), confirming that it is not a rare benign change. This c.3332g>a mutation results in a predicted change of Arg (CGC) at amino acid position 1111 of the ZNF335 protein to His H (CAC) (Figure 2B). Moreover, the c.3332g>a transition is located at the final position of the splice donor site of exon 20, and a G at this position is highly conserved in mammalian splice donor sites (Cartegni et al., 2002).

Northern analysis and RNA-seq from lymphocyte cell lines derived from an affected patient and a heterozygous parent confirmed that the c.3332 g > a mutation disrupted normal splicing. Whereas a cell line from an unrelated individual showed a normal 5 Kb transcript (Figure 2C), both affected patient and heterozygous carriers showed a larger transcript absent in the control, suggesting that the c.3332g>a mutation produces a larger transcript with intron retention. Presence of normally sized transcripts in homozygous mutant lymphocytes suggests that some normally spliced RNA (albeit encoding a p.R1111H mutation) is still formed. RNA-seq of cytoplasmic RNA verified the ZNF335 mutation and also revealed abnormal ZNF335 transcripts with inclusion of both the introns (introns 19, 20) flanking the mutation-containing exon (Figures 2D and S1A) at significantly higher levels than in control cells (p value of $1.57 \times 10^{-23}$).

Western analysis of homozygous patient cells showed severely reduced ZNF335 protein levels at the previously reported size of ~190 kD (Figure 2F). The inclusion of introns 19 and 20 leads to a premature stop codon that could cause transcript degradation (Isken and Maquat, 2007). Yet, a small amount (~16% of control) of full-length, R1111H-mutated protein is still formed, suggesting that some transcript splices normally (Figure 2F), although this mutated protein appears to be less stable (data not shown). No larger protein or degraded protein products were detected in the heterozygous parent or affected patient. Evolutionary analysis of available ZNF335 orthologs indicates that R11111 falls in the 13th zinc finger domain (Figure 2E), which is absolutely conserved in all known ZNF335 sequences (Figure S1B). Interestingly, no clear ZNF335 ortholog can be identified outside of vertebrates. These results are all consistent with the hypothesis that the identified mutation in ZNF335 is the causative mutation in this family. The ortholog in Mus musculus is the Zfp335 gene, but for simplicity, we will use Znf335 throughout this manuscript.

**ZNF335 Is Essential for Early Embryonic Mouse Development**

In order to confirm that ZNF335 is essential in early brain development, we examined mice with engineered null Znf335 mutations and observed that homozygous loss of ZNF335 leads to early embryonic lethality as early as early embryonic day 7.5 (E7.5) (Figures 3A and S2A–S2C). This essential requirement of ZNF335 suggests that the human R1111H mutation could be hypomorphic, as it results in some stable protein, albeit carrying a missense mutation. Examination of 100 individuals with varying degrees of microcephaly—though none as severe—showed no other patients with ZNF335 mutations, suggesting that null ZNF335 mutations in humans may also be lethal. Our data suggest that ZNF335 is essential for normal human brain development and mouse development and prompted us to examine its function.

The pattern and timing of ZNF335 expression are consistent with roles in neurogenesis and potentially other processes as well. Northern analysis of adult (Figure S2A) and embryonic (Figure S2B) human tissues revealed widespread expression of

---

(E) Predicted structure of ZNF335. Mutation lies in the last zinc finger motif.
(F) Western blot of patient lymphoblast cell lines shows that heterozygous parents and homozygous patients produce a reduced amount of full-length ZNF335 protein and shows no evidence of larger or degraded protein products.
See also Figure S1.
Figure 3. ZNF335 Is Essential for Mouse Development and Is Expressed in Nuclei of Progenitor Cells

(A) Location of genetrap insertion of two genetrap mouse lines leading to early truncation of protein to mimic a null allele.
(B) ZNF335 is expressed at E8.5 in developing forebrain (fb), midbrain (mb), somites (S), Branchial arch (ba), and Forelimb bud (flb). Scale bar, 300 μm.
(C) Western blot analysis of ZNF335 protein expression throughout brain development. In the cortex, expression is highest at E13 before tapering off, and expression returns slightly postnatally. ZNF335 is also expressed during the peak of hippocampal and cerebellar development.
(D) Immunohistochemistry shows ZNF335 expression in progenitor cells at E8.5 and in the ventricular zone and subventricular zone of the developing cortex, but not in NeuN+ neurons at E14.5. Protein is also expressed throughout cortical plate later in development. Scale bars, 50, 50, 50, and 400 μm.
ZNF335, including during embryonic brain development. Western analyses of mouse brain tissue show that ZNF335 expression peaks at the height of cortical neurogenesis from E13–E15 (Figure 3C). To localize the expression of ZNF335 in specific cell populations, heterozygous genetrap mice containing a β-galactosidase fusion reporter gene were stained histochemically. ZNF335-lacZ was expressed in the developing forebrain and midbrain of E8.5 embryos (Figures 3B and 3D). Immunofluorescence analysis using antisera raised against ZNF335 confirmed expression in the ventricular zone (VZ) and subventricular zone (SVZ), as well as at lower levels in the developing cortical plate, but showed almost undetectable expression in NeuN-labeled neurons of the cortical plate at E14.5 (Figure 3D). At P5–P30, ZNF335 expression returns at low levels in the adult cerebral cortex, hippocampus, and cerebellum, possibly linked with neuronal maturation (Figures 3C, 3D, 3F, S2D, and data not shown). Higher magnification showed ZNF335 immunoreactivity in nuclei of progenitor cells, where it colocalizes with DAPI-stained DNA (Figure 3E), but it was largely or completely absent from heterochromatic foci. This expression pattern is consistent with roles of ZNF335 in the progenitor cells prenatally and with possible roles in gene expression.

ZNF335 Regulates Neural Progenitor Self-Renewal and Neurogenesis

The expression of ZNF335 in progenitor cells along with the reduced brain size of patients hint at a role in regulating proliferation. In addition, lymphoblast cell lines from patients show decreased growth (Figure 4A), and the p.R1111H mutation leads to decreased ZNF335 binding with Ki-67, a component of a chromatin complex expressed in virtually all proliferating cells and required for growth and survival (Figure S3A) (Garapaty et al., 2009; Zheng et al., 2006). To assess roles of ZNF335 in progenitor proliferation directly, we selectively removed ZNF335 from cerebral cortical progenitor cells by electroporating GFP-expressing plasmids that express either an shRNA (shRNA-ZNF335, Figure S3B–S3C) or an shRNA containing silent mutations, making it unable to target Znf335 (UT-Control). Electroporation was performed into cortical progenitor cells at E9.5 and E12.5. Targeted cells were selected upon dissociation using fluorescent-activated cell sorting (FACS) 24 hr postelectroporation, and the formation of proliferating reaggregate spheres was used to assess progenitor cell proliferation. Knockdown of ZNF335 in both E9.5 and E12.5 progenitors led to a decrease in reaggregate sphere formation (Figure 4B), confirming the role of ZNF335 in progenitor cell proliferation and self-renewal.

In utero electroporation into developing cortices allowed targeting of cortical progenitor cells along the ventricular zone and follow-up studies in the native three-dimensional (3D) architecture of the brain. At 48 hr postelectroporation, fewer ZNF335-depleted cells were observed in the VZ (Figures 4C and 4E), and this phenotype could be rescued by wild-type ZNF335 (WT-ZNF335), but not by mutated ZNF335 (MUT-ZNF335) (Figures 4C, 4E, and S3D). Bromodeoxyuridine (BrdU) pulse-labeling experiments showed that this decrease reflected fewer progenitor cells undergoing DNA synthesis even 24 hr postknockdown (Figure 4F). A BrdU/Ki67 colabeling experiment was performed to mark progenitor cells that either remained in the cell cycle (P fraction) or exited the cell cycle (Q fraction). By 48 hr postknockdown, a greater proportion of targeted progenitor cells exited the cell cycle as compared to UT-Control or wild-type (WT) unelectroporated controls (Figures 4D and 4G). Taken together, these data show that ZNF335 is essential for progenitor self-renewal by maintaining progenitors in the cell cycle and preventing premature cell-cycle exit.

We confirmed the premature cell-cycle exit of ZNF335-depleted cells by allowing electroporated mice to develop until adulthood. A higher proportion of ZNF335-depleted neurons occupied deeper layers of the cortex (Figure 4H, 4I), consistent with early cell-cycle exit, and fewer occupied more superficial layers, the location of later born neurons. ZNF335-depleted neurons also exhibited abnormal cell fates. Whereas most control neurons were Cux1 positive and FoxP1 negative (markers of layers II–IV and III–V, respectively), knockdown neurons instead took on the identity of lower-layer, earlier born neurons (Cux1 negative, FoxP1 positive) (Figures 5A and 5C). These data indicate that ZNF335 deficiency leads to premature neuronal fate determination, which causes a depletion of dividing cells and is consistent with our patient phenotype of reduced cortical size and abnormal cortical layering.

ZNF335 Also Regulates Neuronal Morphogenesis and Dendrite Outgrowth

Further analysis of ZNF335-depleted neurons demonstrates abnormal neuronal morphology reminiscent of the patient histology (Figures 1B and 1D). Knockdown cells at P0 showed abnormal cell orientation and radial glia (Figure 5Ba and 5Bb). By P6 and P8, knockdown neurons showed smaller cell bodies and lacked normal vertical apical dendritic process (Figure 5Bc–5Bf). By P16, the dendritic outgrowth of knockdown cells was disorganized and abnormally oriented (Figures 5Bg and 5Bh), and only 25% of cells showed dendrites oriented perpendicular to the pial surface, versus 95% in controls (Figure 5D). By adulthood, knockdown neurons showed disorganized branching, abnormal orientation, and signs of breakdown in dendrites (Figure 5Bi–5Bn). WT-ZNF335, but not MUT-ZNF335, rescued the orientation phenotype, confirming the specificity of this phenotype and that the p.R1111H mutation is deficient but likely hypomorphic (Figure 5D). These phenotypes are reminiscent of the sparse neurons with reduced dendrites and abnormal orientation seen in patient histology studies. Microarray analysis of neurons with decreased ZNF335 expression showed decreased expression of genes.
Figure 4. ZNF335 Is Essential for Progenitor Cell Proliferation and Cell-Cycle Maintenance

(A) Growth curves of lymphoblast cell lines derived from heterozygous parent (Het), homozygous patient (Hom), and control shows decreased growth rate in cells from patient with low levels of mutated ZNF335. E9.5: UT-Control, 15.25 ± 4.3; shRNA-ZNF335, 7.1 ± 2.9, t test, p = 0.0032, n = 6; E12.5 UT-Control, 82.2 ± 11.5; shRNA-ZNF335, 51.6 ± 11.6, T test, p = 0.001; n = 6 rounds of FACS sorting, mean ± SD. Each sort is from pooled embryos from three different dams with roughly half of their embryos electroporated with either shRNA-ZNF335 or UT-control constructs.

(B) Knockdown of ZNF335 leads to decreased formation of progenitor cell reaggregates in E9.5 and E12.5 progenitor cell cultures showing decreased proliferation upon knockdown of ZNF335. WT-ZNF335 rescues the number of progenitors, but MUT-ZNF335 does not. Scale bar, 10 μm.
that are important for brain development, such as neuron-specific transcription factors, dendritic branching and pruning genes, cell-cycle and specific signaling factors, and neuronal-specific microtubule-binding partners (Figure S4), all of which could contribute to the neuronal and patient phenotypes.

**ZNF335 Interacts with a Chromatin-Remodeling Complex**

In order to elucidate how loss of ZNF335 could have such broad roles, we identified candidate-interacting proteins by immunoprecipitating (IP) FLAG-tagged ZNF335 in stable HeLaS3 cell lines as well as from endogenous E14.5 developing mouse brain lysates. Experiments utilizing IP followed by mass spectrometry (MS) and western verification revealed that ZNF335 pulls down members of a human H3K4 methyltransferase complex such as MLL, SETD1A, CFP1, ASH2, RbBP5, and WDR5 and that the complex components have histone H3 methyltransferase activity (Figure 6A and Table S1) (Garapaty et al., 2009; Schuettengruber et al., 2011). Together, these proteins form a complex analogous to that of the TrxG complex in *Drosophila* or the complex COMPASS (complex proteins associated with Set1) in *Saccharomyces cerevisiae*—both required for specific activation of gene expression (Schuettengruber et al., 2011).

Knockdown of members of this methyltransferase complex cause stunted embryonic development and death, whereas WDR5 expression activates self-renewal genes in embryonic stem cells (Ang et al., 2011). The interaction of ZNF335 with a H3K4 methyltransferase complex presents an avenue for the regulation of many genes, consistent with the widespread effects in the brain and other tissues upon ZNF335 loss.

**ZNF335 Regulates Histone Methylation and Expression of Specific Genes**

Chromatin IP followed by deep sequencing (ChiP-seq) identified ZNF335-bound promoters representing possible ZNF335-regulated genes. ChiP-seq was performed on developing mouse E14.5 lateral telencephalon with two separate antisera and two biological replicates. ZNF335 peaks overlapped with promoter regions (Figures 6B, 6C, and S5) of a variety of genes, for example, genes that play roles in cell proliferation, somatic development, cell death, neuronal maturation, and signaling pathways, among others (Figure S5 and Table S2). Because ZNF335 interacts with a methyltransferase complex, we looked at the methylation patterns of these ZNF335-bound promoters (Shen et al., 2012), and the peaks of ZNF335 binding overlapped with the H3K4 trimethylation (H3K4me3) peaks (Figure S5A). Similarly, in patients with decreased ZNF335, H3K4me3 marks at the promoters of ZNF335-bound genes were also decreased, whereas control H3K27me3 marks were unchanged (Figure S5B). Finally, because H3K4me3 is linked with gene expression, RNA-seq data from the parents and patients with low H3K4me3 marks also showed decreased expression of these ZNF335 target genes (Figure S5C and Table S2). Together, these data hint at a role of ZNF335 in a methyltransferase complex that is important for the H3K4 trimethylation and ultimately the expression levels of a large variety of genes. GeneGo analysis performed on the genes identified through ChiP-seq, microarrays, and RNA-seq data from patients showed that the genes affected by ZNF335 were involved in a variety of pathways that are important for both somatic development and brain development (Tables S3–S6).

**ZNF335 Is Upstream of REST/NRSF**

Interestingly, we observed ZNF335 bound to the promoter region of the known progenitor cell master regulator REST/NRSF (Figure 6B). A direct relationship between ZNF335 and expression of REST/NRSF is suggested by decreased TrxG complex binding and decreased H3K4me3 marks at the REST/NRSF promoter (Figures 6D and 6E), as well as by decreased mRNA levels of REST/NRSF in ZNF335 mutant patients (Figure 6E). Decreased REST/NRSF expression was seen upon ZNF335 knockdown of HeLa and Hek293 cells (Figure 6G), supporting a close and potentially direct relationship. Conversely, expression of a dominant-negative REST (DN-REST), which contains the DNA-binding domain only (Chong et al., 1995; Schoenhere and Anderson, 1995), as well as overexpression of REST/NRSF, did not significantly alter ZNF335 expression (Figure 6H). Rescue experiments also showed that premature cell-cycle exit and premature migrating neurons in the absence of ZNF335 could be rescued by REST, but not by DN-REST, which caused a phenotype similar to ZNF335 deficiency (Figure 6J). These data, along with the promoter binding of REST/NRSF by ZNF335, suggest direct regulation of REST/NRSF expression by ZNF335 (Figure 6I) and provide an avenue for...
Figure 5. ZNF335 Deficiency Leads to Decreased Cell Size and Abnormal Dendritic Shape and Orientation

(A) Knockdown of ZNF335 leads to reduction of cells in the cortical plate and production of Cux1-negative (white circles) and FoxP1-positive (blue circles) cells showing a change in cell fate. Dashed line represents end of zone containing GFP-positive cells. Scale bar, 50 μm.

(B) Knockdown and control cells were targeted at E14.5 and analyzed at P0 (a and b), P6 (c and d) to show abnormal radial glia (P0, arrowhead) and abnormal cell body shape and size (P6, dashed circle). There is abnormal dendritic arborization (arrowhead) and orientation in knockdown cells at P8 (e and f) and P16 (g and h) and signs of breakdown in dendrites at P22 (i, j, and k) and P30 (l, m, and n). Scale bar, 50 μm.

(C) Analysis of (A). Knockdown showed production of more Cux1-negative cells as compared to control and production of more FoxP1-positive cells as compared to control.

Table:

<table>
<thead>
<tr>
<th></th>
<th>Cux1+</th>
<th>Cux1-</th>
<th>FoxP1+</th>
<th>FoxP1-</th>
</tr>
</thead>
<tbody>
<tr>
<td>UT-Control</td>
<td>95.5 +/- 4.5</td>
<td>4.5 +/- 4.5</td>
<td>5.4 +/- 3.9</td>
<td>94.6 +/- 3.9</td>
</tr>
<tr>
<td>shRNA</td>
<td>88.2 +/- 3.6</td>
<td>12.8 +/- 3.6</td>
<td>34.3 +/- 8.6</td>
<td>65.7 +/- 8.6</td>
</tr>
</tbody>
</table>

(D) Orientation of primary process
abnormal neurogenesis secondary to abnormal REST/NRSF regulation.

**Roles of ZNF335 in Neuronal Production and Differentiation**

Further analysis of ZNF335 knockdown neurons showed stereotypical neuronal morphology (small cell bodies, dendrites, axons) but, with a surprising loss of immunoreactivity for D11Bwg0517e/Fox3, or neuronal nuclei (NeuN), a ubiquitous marker of all differentiated neurons (Dredge and Jensen, 2011) (Figures 7A, 7B, and S6A), suggesting an apparent state of incomplete neuronal differentiation. This failure to express mature neuronal markers could reflect the abnormal premature neurogenesis caused by early progenitor cell-cycle exit (Figure 4D) or, perhaps more likely, could reflect direct requirements for ZNF335 in controlling gene expression in postmitotic neurons or in neuronal maturation and activity. The altered morphology (Figure 5B) and the arrested development (Figure 7A) exhibited by ZNF335 knockdown neurons are reminiscent of the altered neuronal phenotype, cortical layers, and cortical size seen in patients (Figures 1B and 1C).

Similar to ZNF335-depleted cortical neurons, ZNF335 knockdown in cerebellar granule cells produced abnormal cell migration, morphology, and differentiation. ZNF335-deficient cerebellar granule cells showed migration arrest with decreased migration into the IGL (Figures S6B and S6C) recapitulating the human phenotype (Figures 1D and 1E). Microarray (Figure S4) and immunohistochemistry (Figures 7C and 7D) of ZNF335-deficient cells showed decreased Mef2C expression, suggesting an arrest of normal transcriptional patterns. Our findings that knockdown of ZNF335 leads to increased cell death (Figure S6D) might suggest that this effect is mediated through changes in Mef2c expression (Mao et al., 1999).

Finally, to confirm the essential role of ZNF335 in cerebral cortical neurogenesis, we created a brain-specific, conditional knockout (Figure 3A). Emx1-Cre-mediated removal of ZNF335 (ZNF335 CKO) (Figure S7) produced a brain with an essentially absent cortex lacking all cortical neurons at sites of Emx1 expression (Figures 7E and 7F) (Gorski et al., 2002) and with a modest reduction in cortical size in heterozygotes compared to controls (Figure 7E). The lack of cortical plate and cortical neurons is in accordance with the essential role of ZNF335 in progenitor cells and postmitotic neurons. The small brain phenotype of the ZNF335 CKO further confirms that ZNF335 is responsible for the severe phenotype seen in our patients and verifies ZNF335 as a new microcephaly gene that is essential for neurogenesis and differentiation.

**DISCUSSION**

Here, we identify ZNF335/NIF1 as a central regulator of mammalian neurogenesis and neuronal differentiation. A splice donor/misense mutation of ZNF335 results in an extremely small brain in humans, and genetic ablation leads to early embryonic lethality in mice, whereas Emx1-Cre-driven knockout leads to virtual absence of cortical structure. Loss of ZNF335 causes premature cell-cycle exit of progenitors, precociously depleting the progenitor pool. ZNF335 is a part of a H3K4 methyltransferase complex and associates with the promoters of many key developmental genes to affect H3K4me3, as well as expression levels of target genes. A critical downstream target of ZNF335 is REST/NRSF, representing a pathway that is critical for this neurogenetic function. Beyond its effects on progenitor cell proliferation, ZNF335 also has essential effects on cell fate and cell morphology (and ultimately survival).

Despite the profound phenotype of ZNF335 mutation in humans, the mutation that we describe is almost certainly hypomorphic. Overexpression of the human mutation can only partially rescue ZNF335 deficiency, and conditional ablation of ZNF335 in mouse cortex results in loss of essentially the entire cortex. Thus, null mutations in ZNF335 in humans are presumably embryonically lethal as in mice, illustrating the utility of unusual, partial loss-of-function mutations in humans to elucidate essential early embryonic functions of such genes.

This study provides direct insight into the function of TrxG complex proteins in embryonic neurogenesis. The interaction of ZNF335 with proteins of the H3K4 methyltransferase complex suggests roles for ZNF335 in the regulation, targeting, or stability of the complex. Epigenetic regulation causes programming of gene expression, and specific histone methylation can further orchestrate gene regulation in a cell-type- and tissue-dependent manner. Mutations in neural-specific chromatin regulatory complexes, nBAF, have been shown to affect proliferation and are linked with microcephaly (Hoyer et al., 2012). Thus, this interaction provides a potential parallel for the broad effects of the ZNF335 mutation on human patients and the large number of genes and developmental processes altered by ZNF335 knockdown, as well as the embryonic lethality in Znf335 null mice, especially as knockouts of other histone methyltransferases are also lethal embryonically (Glaser et al., 2009).

Loss of ZNF335 alters expression levels of many key genes, including DLX homeobox genes (early brain development), Neurogenin, Nfib, Olig1, Math1, REST/NRSF, and Co-REST 2 (neurogenesis), among many other genes that are important for dendritic branching, cell adhesion, and signaling. Changes in these genes could explain phenotypes seen in the patients.
Figure 6. ZNF335 Interacts with Trithorax Complex Proteins and Is Upstream of Many Neuronal Differentiation Genes, Including REST/NRSF
(A) Blots show coimmunoprecipitation of ZNF335 with members of the trithorax complex in human HeLaS3 cell lines and mouse E14.5 cortex, indicating an interaction of ZNF335 with the histone methyltransferase complex.
(B) ZNF335 binds to promoter region of REST/NRSF, and binding overlaps with the H3K4me3 marks.
(C) Promoter binding consensus motif for ZNF335 with GAGAG motif that is predicted for C2H2 zinc fingers (Omichinski et al., 1997).
(D) Decreased binding of trithorax complex proteins such as WDR5 to the REST promoter under low levels of ZNF335. WDR5: control: 1.09 ± 0.48, Het parent: 0.16 ± 0.25, Hom patient: 0.28 ± 0.27; mean ± SD, p < 0.0001; chromatin was obtained and compiled from three different growth cultures. Two IPs were performed for each pooled set of chromatin isolated from lymphoblast cell lines, and qPCR was run in triplicates in comparison to input. All qPCR runs were normalized to GAPDH.
and correlate with abnormal neurogenesis evident in mouse models and account for the virtual absence of cortical neurons in the ZNF335 CKO. Genes whose expression changes upon ZNF335 deficiency could be primary targets of ZNF335 or secondary to other regulatory genes downstream of ZNF335, such as REST/NRSF, but reveal ZNF335 as a critical regulator of gene expression that is essential for proper neuronal development.

ZNF335 also regulates differentiation and gene transcription in postmitotic neurons. ZNF335 deficiency blocks normal expression of “canonical” neuronal marker genes, such as NeuN and Met2C, which either could be a secondary effect of premature and improper neurogenesis or may hint at a role of ZNF335 in regulating cell identity, survival, and activity of mature neurons. ZNF335 regulates a variety of non-REST/NRSF targets that are important for the final stages of neuronal differentiation, such as genes regulating dendritic branching, and ion channels, which may suggest roles of ZNF335 in other neuron-specific transcriptional complexes.

Genetic causes of microcephaly continue to grow in diversity and include proteins involved in vesicle trafficking, mitotic spindle organization, and DNA repair (Thornton and Woods, 2009). Premature neuronal fate specification, with consequent loss of progenitor cells, could be a frequent cellular mechanism resulting in microcephaly (Lehtinen and Walsh, 2011). ZNF335 deficiency causes the additional feature of neuronal degeneration, making it strikingly different and more severe than other microcephaly syndromes, which are typically compatible with postnatal survival and, in many cases, some intellectual function. Thus, our data reveal ZNF335 as a unique type of microcephaly gene and provide evidence of a new upstream regulator of the balance between progenitor cell division and differentiation.

**EXPERIMENTAL PROCEDURES**

**Human Patients**

Peripheral blood samples were collected from patients and unaffected family members, and mapping was performed using single-nucleotide polymorphism (SNP) arrays and microsatellite markers to narrow down the boundaries of shared homozygosity. All coding exons were sequenced in the area of homozygosity on chromosome 20q13.2 to reveal the only homozygous coding mutation in the gene ZNF335. All human studies were reviewed and approved by the institutional review board of the Boston Children’s Hospital, the Beth Israel Deaconess Medical Center, and local institutions.

**Animals**

Timed pregnant CD1 and Swiss Webster dams (Charles River Laboratories and Taconic). Genetrap 1 and 2 (AY0030 and XG241) (The Genetrap Consortium). Ex utero and in utero electroporations were performed on timed pregnant E9.5–E14.5 embryos. All animal experimentation was carried out under protocols approved by the IACUCs of Harvard Medical School and Boston Children’s Hospital.

**Culture Systems**

Primary cortical neurons were isolated from E14.5 mouse cells and dissociated by the Papain Dissociation System (Worthington Biochem. Corp.). Cells were grown on Poly-L-Ornithine-coated plates (Sigma) in Neurobasal ( Gibco) with 0.6% glucose, B27 ( Gibco), N2 ( Gibco), 1 mM Penicillin, streptomycin, and L-glutamine and were transfected 1 hr postplating. Primary granule neurons were isolated from P5 mouse pups and grown on Poly-L-Ornithine-coated coverslips in basal medium ( Eagle, Gibco), with 10% calf serum (HyClone), 1 mM Penicillin, streptomycin, L-glutamine, and 25 mM KCl. Neurons were transfected 2 days postplating with calcium phosphate. All experiments were analyzed in a double-blind manner using an unpaired t test.

**CO-IP/Mass Spectrometry**

See Extended Experimental Procedures.

**RNA-Sequencing**

See Extended Experimental Procedures.

**ChIP-Sequencing**

ChIP-seq was performed on E14.5 cortical tissue with antisera against ZNF335/NIF1 (Bethyl 797, 798A). 1–10 ng of ChIP DNA was used to prepare libraries sequenced at Ellum Biopharmaceuticals, Inc. Peaks were identified by MACS, and gene names were identified using custom Python scripts. All of the raw ChIP-seq data were deposited to NCBI’s Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) (deposition number GSE38385). Functional characterization of genes was carried out according to the GO rules by MetaCore (http://www.genego.com/genego_ip.php), See Extended Experimental Procedures.
Figure 7. ZNF335 Is Essential for Neuronal Differentiation and Brain Development

(A) Knockdown of ZNF335 leads to presence of NeuN− cells (blue circles) that nonetheless have neuronal morphology in 14 day culture systems. NeuN is a marker of differentiated neurons. Scale bar, 20 μm.

(B) Quantification of NeuN+ and NeuN− cells upon knockdown of ZNF335 in short- and long-term culture shows decreased production of NeuN+ cells over long-term culture. Control NeuN+: 4 day: 48.2 ± 14.1; 7 day: 81.5 ± 12.1; 10 day: 100 ± 0.9; 14 day: 100 ± 1.5; shRNA-ZNF335 NeuN+: 4 day: 30.7 ± 12.3; 7 day: 50.0 ± 7.0; 10 day: 35.7 ± 18.1; 14 day: 22.9 ± 19.1]; mean ±SD, t test, 7, 10, 14 day: p < 0.0001; n = 12 separate cortical neuron cultures from 12 litters.

(C) Knockdown of ZNF335 leads to Mef2C− cells (arrows), whereas UT-control shows Mef2C+ cells (arrowhead). Scale bar, 20 μm.

(D) Quantification of Mef2C+ and Mef2C− cells shows decreased production of Mef2C+ cells upon knockdown of ZNF335 in short- and long-term cultures. Control Mef2C+: 9 day: 100 ± 0.8; 16 day: 93.0 ± 8.2; shRNA-ZNF335 Mef2C+: 9 day: 48.5 ± 2.1; 16 day: 44.0 ± 15.2; mean ±SD, t test, 9 day: p = 0.0018, 16 day: p = 0.008; n = 3 separate granule cell cultures from 3 different litters.
ZFNS35 CKO

Floxed allele was generated in a mixed C57/B16 and 129B6 background that would lead the removal of the Znf335 promoter and exons 1 and 2. See Extended Experimental Procedures.

ACCESSION NUMBERS

All of the raw ChIP-seq data were deposited to NCBI’s Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) with the deposition number GSE36835 for genome-wide maps of Znf335 localization in embryonic cortical tissue at E14.5. Microarray data were deposited with the deposition number GSE36384 (Control) and GSE36386 (knockdown).

SUPPLEMENTAL INFORMATION

Supplemental Information includes Extended Experimental Procedures, seven figures, and seven tables and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2012.10.043.

ACKNOWLEDGMENTS

We thank D. Moazed, M.E. Hatten, B. Ren, D.M. Ferrero, and members of the Walsh laboratory for helpful discussions; L. Shechtman for tissue; N. Dwyer for early mapping; G. Mandel for DN-REST construct; E.E. Govek for help with cerebellar slices; K.S. Krishnamoorthy for control MRIs; and D.J. Tischfield, L.B. Hills, K.D. Atabay, P.P. Wang, J. Wertzol, D.G. Tierney, and J.M. Felle for technical assistance. This work was supported by a Stuart H.Q. and Victoria Quan Fellowship (Y.J.Y.); a NIH MSTP grant T32GM007753 (Y.J.Y. and G.D.E.); a NIH T32 HD007466 (A.E.B.); The Damon Runyon Cancer Research Foundation DRG-2042-10 (R.S.M.); HHHI Medical Research Fellows Program (E.P.W.); R01 DK16636 (H.H.S.); NIH grants (GM058012, GM071004, and CA118487) (Y.S.); grants from the NINDS (R01 NS032457 and R01 NS53199); and the Manton Center for Orphan Disease Research (C.A.W.). C.A.W. is an Investigator of the Howard Hughes Medical Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIH.

Received: March 15, 2012
Revised: July 27, 2012
Accepted: October 17, 2012
Published: November 21, 2012

REFERENCES


